Mantle Cell Lymphoma
Telecommunications · New York, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
90 West St Apt 12M, New York, New York, ...Phone Number
(844) 627-7246Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Mantle Cell Lymphoma
Mantle Cell Lymphoma is a company that operates in the Telephony & Wireless industry. It employs 10to19 people and has 1Mto5M of revenue. The company is headquartered in New York City, New York.Explore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Mantle Cell Lymphoma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Earning: See what the market has to say on Mantle Cell Lymphoma recently announced quarterly report
Funding: Get notified immidiatlly once Mantle Cell Lymphoma has new funding data
Click to see if Mantle Cell Lymphoma had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Mantle Cell Lymphoma, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Mantle Cell Lymphoma
Website visits: Recent activity has been detected on your website
Check if Mantle Cell Lymphoma has recently received funding, and reach out quickly before it becomes old news!
Check out if Mantle Cell Lymphoma is spiking on competitors!
Product Launch: Get notified when Mantle Cell Lymphoma launches new products
Recommended Actions
Reach out to Masked Content who joined Mantle Cell Lymphoma as Masked Content
Find more new buyers
Compare Similar Companies to Mantle Cell Lymphoma
Compare insights from companies similar to Mantle Cell Lymphoma, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Mantle Cell Lymphoma
<$5M
1-10
Private
-
-
N/A
Company Profile Activity
Activity Insights
Mantle Cell Lymphoma is experiencing very low activity levels compared to other companies in the Telecommunications sector.
What does this means?
Mantle Cell Lymphoma is drawing exceptional interest within the Telecommunications industry, suggesting notable developments or strong market momentum, learn more about Mantle Cell Lymphoma.
Mantle Cell Lymphoma Tech Stack
A closer look at the technologies used by Mantle Cell Lymphoma
See more technologies
Mantle Cell Lymphoma News & Media
CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The Food and Drug Administration (FDA) grants Priority Review to applications for medicines that, if approved, would offer significant improvements over available options by demonstrating safety or efficacy improvements, preventingCALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive results from the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with bendamustine and rituximab demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) and showed a favorable trend in overall survival (OS) compared to standard-of-care chemoimmunotherapy (bendamustine plus rituximab) in previously untreated patients with mantle cell lymphoma (MCL). These resuCALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with standard-of-care chemoimmunotherapy, bendamustine and rituximab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus standard of care in previously untreated adult patients with mantle cell lymphoma (MCL). A trend was observed in favor of CALQUENCalquence combination improved PFS in 1L MCL
02 May 2024 Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial First BTK inhibitor to show favourable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting Positive high-level results from an interim analysis of the ECHO Phase III trial showed AstraZeneca's Calquence (acalabrutinib) in combination with standard-of-care chemoimmu
Read more news
Top Telecommunications Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Mantle Cell Lymphoma
Sign Up For FreeTo access detailed company insights
Mantle Cell Lymphoma is a company that operates in the Telephony & Wireless industry. It employs 10to19 people and has 1Mto5M of revenue. The company is headquartered in New York City, New York.... Read More
